Dinis Martins

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

Gregory G. Schwartz, Michael Szarek, Vera Bittner et al. · Diabetes Care · 2021 · 38 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dabigatran reversal with idarucizumab in a patient undergoing heart transplantation: first European report

António Tralhão, Carlos Aguíar, Jorge Ferreira et al. · Thrombosis Journal · 2017 · 19 citations · Full text

Medicine, Cardiology, Pharmacology +17

Cysteine is a better predictor of coronary artery disease than conventional homocysteine in high-risk subjects under preventive medication

Ana Lima, Rita Ferin, A Fontes et al. · Nutrition Metabolism and Cardiovascular Diseases · 2020 · 15 citations

Medicine, Cardiology, Preventive Medicine +10